The course of insomnia symptoms during the acute treatment of major depressive disorder: A CAN-BIND-1 report

•Limited research on changes in insomnia symptoms with antidepressant pharmacotherapy.•We investigated the course of insomnia symptoms during acute treatment of MDD.•MDD patients were treated with open-label escitalopram (10–20 mg/day) for 8-weeks.•Remitters had lower QIDS-SR sleep-onset and mid-noc...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 2023-07, Vol.325, p.115222-115222, Article 115222
Main Authors: Dama, Manish, Wu, Michelle, Tassone, Vanessa K., Demchenko, Ilya, Frey, Benicio N., Milev, Roumen V., Ravindran, Arun V., Parikh, Sagar V., Rotzinger, Susan, Lou, Wendy, Lam, Raymond W., Kennedy, Sidney H., Bhat, Venkat
Format: Article
Language:English
Subjects:
Antidepressive agents
Insomnia
Major depressive disorder
Sleep
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Limited research on changes in insomnia symptoms with antidepressant pharmacotherapy.•We investigated the course of insomnia symptoms during acute treatment of MDD.•MDD patients were treated with open-label escitalopram (10–20 mg/day) for 8-weeks.•Remitters had lower QIDS-SR sleep-onset and mid-nocturnal insomnia scores.•Remitters also had lower PSQI sleep quality score than non-remitters. Despite considerable efforts to study the relationship between insomnia and depression, there is minimal research investigating whether insomnia symptoms change over time during a course of antidepressant pharmacotherapy. This study investigated the course of insomnia symptoms during the acute treatment of major depressive disorder (MDD) using a secondary analysis of data from MDD patients (N = 180) who were treated with open-label escitalopram (10–20 mg/day) for 8-weeks. Montgomery-Asberg Depression Rating Scale without sleep item (modified-MADRS) assessed depression and Self-reported Quick Inventory Depressive Scale (QIDS-SR) measured subjective sleep-onset, mid-nocturnal, and early-morning insomnia throughout 8-weeks of treatment. Pittsburgh Sleep Quality Index (PSQI) was used to assess subjective sleep quality, duration, onset latency, and efficiency throughout 8-weeks of treatment. Remission of depression was defined as modified-MADRS ≤10 at week-8. Mixed model repeated measures (MMRMs) were conducted with remission status as an independent variable and each sleep variable as a dependent variable. MMRMs demonstrated that remitters had significantly lower QIDS-SR sleep-onset and mid-nocturnal insomnia scores as well as a significantly lower PSQI sleep quality score than non-remitters throughout 8-weeks of treatment. Monitoring subjective sleep-onset and mid-nocturnal insomnia during the course of treatment with serotonergic antidepressants may be useful for predicting acute remission of depression.
ISSN:0165-1781
1872-7123
DOI:10.1016/j.psychres.2023.115222